7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel ROCK inhibitor blocks cytoskeleton function and cell migration

Chih Chien Tsai, Huei Fang Liu, Kai Cheng Hsu, Jinn Moon Yang, Chinpiao Chen, Kuang Kai Liu, Tzu Sheng Hsu, Jui I. Chao

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The 5,8-quinolinediones are precursors for producing multiple types of bioactive products. In this study, we investigated a new compound derived from 5,8-quinolinediones, 7-chloro-6-piperidin-1-yl-quinoline-5,8-dione (designated as PT-262), which markedly induced cytoskeleton remodeling and migration inhibition in lung carcinoma cells. Comparison with various cytoskeleton inhibitors, including paclitaxel, colchicine and phallacidin, the cell morphology following treatment with PT-262 was similar to phallacidin on the cell elongation and abnormal actin polymerization. However, PT-262 did not directly bind to actin filaments. ROCK (Rho-associated coiled-coil forming protein kinase) is a downstream effector of RhoA to mediate the phosphorylation of myosin light chain (MLC) and cytoskeleton reorganization. The RhoA-ROCK-MLC pathway has been shown to promote cancer cell migration and metastasis. Interestingly, PT-262 was more effective on inhibiting ROCK kinase activities than specific ROCK inhibitors Y-27632 and H-1152. PT-262 induced cytoskeleton remodeling and migration inhibition in A549 lung carcinoma cells. The total MLC and phosphorylated MLC proteins and stress fibers were blocked after treatment with PT-262. Nonetheless, the RhoA protein and GTPase activity were not altered by PT-262. A computational model suggests that PT-262 interacts with the ATP-binding site of ROCK protein. Together, these findings demonstrate that PT-262 is a new ROCK inhibitor.

Original languageEnglish
Pages (from-to)856-865
Number of pages10
JournalBiochemical Pharmacology
Volume81
Issue number7
DOIs
Publication statusPublished - Apr 1 2011
Externally publishedYes

Fingerprint

Cytoskeleton
Cell Movement
Myosin Light Chains
Cells
Actins
rhoA GTP-Binding Protein
Carcinoma
quinoline
7-chloro-6-piperidin-1-ylquinoline-5,8-dione
Lung
Stress Fibers
Phosphorylation
GTP Phosphohydrolases
Colchicine
Heat-Shock Proteins
Paclitaxel
Actin Cytoskeleton
Polymerization
Protein Kinases
Elongation

Keywords

  • Cell migration
  • Cytoskeleton
  • Lung cancer
  • PT-262
  • ROCK

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry

Cite this

7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel ROCK inhibitor blocks cytoskeleton function and cell migration. / Tsai, Chih Chien; Liu, Huei Fang; Hsu, Kai Cheng; Yang, Jinn Moon; Chen, Chinpiao; Liu, Kuang Kai; Hsu, Tzu Sheng; Chao, Jui I.

In: Biochemical Pharmacology, Vol. 81, No. 7, 01.04.2011, p. 856-865.

Research output: Contribution to journalArticle

Tsai, Chih Chien ; Liu, Huei Fang ; Hsu, Kai Cheng ; Yang, Jinn Moon ; Chen, Chinpiao ; Liu, Kuang Kai ; Hsu, Tzu Sheng ; Chao, Jui I. / 7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel ROCK inhibitor blocks cytoskeleton function and cell migration. In: Biochemical Pharmacology. 2011 ; Vol. 81, No. 7. pp. 856-865.
@article{4e11c6bc06aa40fd88e9144f1bb8d991,
title = "7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel ROCK inhibitor blocks cytoskeleton function and cell migration",
abstract = "The 5,8-quinolinediones are precursors for producing multiple types of bioactive products. In this study, we investigated a new compound derived from 5,8-quinolinediones, 7-chloro-6-piperidin-1-yl-quinoline-5,8-dione (designated as PT-262), which markedly induced cytoskeleton remodeling and migration inhibition in lung carcinoma cells. Comparison with various cytoskeleton inhibitors, including paclitaxel, colchicine and phallacidin, the cell morphology following treatment with PT-262 was similar to phallacidin on the cell elongation and abnormal actin polymerization. However, PT-262 did not directly bind to actin filaments. ROCK (Rho-associated coiled-coil forming protein kinase) is a downstream effector of RhoA to mediate the phosphorylation of myosin light chain (MLC) and cytoskeleton reorganization. The RhoA-ROCK-MLC pathway has been shown to promote cancer cell migration and metastasis. Interestingly, PT-262 was more effective on inhibiting ROCK kinase activities than specific ROCK inhibitors Y-27632 and H-1152. PT-262 induced cytoskeleton remodeling and migration inhibition in A549 lung carcinoma cells. The total MLC and phosphorylated MLC proteins and stress fibers were blocked after treatment with PT-262. Nonetheless, the RhoA protein and GTPase activity were not altered by PT-262. A computational model suggests that PT-262 interacts with the ATP-binding site of ROCK protein. Together, these findings demonstrate that PT-262 is a new ROCK inhibitor.",
keywords = "Cell migration, Cytoskeleton, Lung cancer, PT-262, ROCK",
author = "Tsai, {Chih Chien} and Liu, {Huei Fang} and Hsu, {Kai Cheng} and Yang, {Jinn Moon} and Chinpiao Chen and Liu, {Kuang Kai} and Hsu, {Tzu Sheng} and Chao, {Jui I.}",
year = "2011",
month = "4",
day = "1",
doi = "10.1016/j.bcp.2011.01.009",
language = "English",
volume = "81",
pages = "856--865",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - 7-Chloro-6-piperidin-1-yl-quinoline-5,8-dione (PT-262), a novel ROCK inhibitor blocks cytoskeleton function and cell migration

AU - Tsai, Chih Chien

AU - Liu, Huei Fang

AU - Hsu, Kai Cheng

AU - Yang, Jinn Moon

AU - Chen, Chinpiao

AU - Liu, Kuang Kai

AU - Hsu, Tzu Sheng

AU - Chao, Jui I.

PY - 2011/4/1

Y1 - 2011/4/1

N2 - The 5,8-quinolinediones are precursors for producing multiple types of bioactive products. In this study, we investigated a new compound derived from 5,8-quinolinediones, 7-chloro-6-piperidin-1-yl-quinoline-5,8-dione (designated as PT-262), which markedly induced cytoskeleton remodeling and migration inhibition in lung carcinoma cells. Comparison with various cytoskeleton inhibitors, including paclitaxel, colchicine and phallacidin, the cell morphology following treatment with PT-262 was similar to phallacidin on the cell elongation and abnormal actin polymerization. However, PT-262 did not directly bind to actin filaments. ROCK (Rho-associated coiled-coil forming protein kinase) is a downstream effector of RhoA to mediate the phosphorylation of myosin light chain (MLC) and cytoskeleton reorganization. The RhoA-ROCK-MLC pathway has been shown to promote cancer cell migration and metastasis. Interestingly, PT-262 was more effective on inhibiting ROCK kinase activities than specific ROCK inhibitors Y-27632 and H-1152. PT-262 induced cytoskeleton remodeling and migration inhibition in A549 lung carcinoma cells. The total MLC and phosphorylated MLC proteins and stress fibers were blocked after treatment with PT-262. Nonetheless, the RhoA protein and GTPase activity were not altered by PT-262. A computational model suggests that PT-262 interacts with the ATP-binding site of ROCK protein. Together, these findings demonstrate that PT-262 is a new ROCK inhibitor.

AB - The 5,8-quinolinediones are precursors for producing multiple types of bioactive products. In this study, we investigated a new compound derived from 5,8-quinolinediones, 7-chloro-6-piperidin-1-yl-quinoline-5,8-dione (designated as PT-262), which markedly induced cytoskeleton remodeling and migration inhibition in lung carcinoma cells. Comparison with various cytoskeleton inhibitors, including paclitaxel, colchicine and phallacidin, the cell morphology following treatment with PT-262 was similar to phallacidin on the cell elongation and abnormal actin polymerization. However, PT-262 did not directly bind to actin filaments. ROCK (Rho-associated coiled-coil forming protein kinase) is a downstream effector of RhoA to mediate the phosphorylation of myosin light chain (MLC) and cytoskeleton reorganization. The RhoA-ROCK-MLC pathway has been shown to promote cancer cell migration and metastasis. Interestingly, PT-262 was more effective on inhibiting ROCK kinase activities than specific ROCK inhibitors Y-27632 and H-1152. PT-262 induced cytoskeleton remodeling and migration inhibition in A549 lung carcinoma cells. The total MLC and phosphorylated MLC proteins and stress fibers were blocked after treatment with PT-262. Nonetheless, the RhoA protein and GTPase activity were not altered by PT-262. A computational model suggests that PT-262 interacts with the ATP-binding site of ROCK protein. Together, these findings demonstrate that PT-262 is a new ROCK inhibitor.

KW - Cell migration

KW - Cytoskeleton

KW - Lung cancer

KW - PT-262

KW - ROCK

UR - http://www.scopus.com/inward/record.url?scp=79952573259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952573259&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2011.01.009

DO - 10.1016/j.bcp.2011.01.009

M3 - Article

VL - 81

SP - 856

EP - 865

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 7

ER -